Newsletter ESC 2018

#ACC20/#WCCardio | [3/3] Sacubitril/valsartan group had a larger increase in KCCQ at 12 weeks vs control and were more likely to have a ≥5-pt and ≥20-pt response vs control. pic.twitter.com/x0Bx34yjlb

Ieri dal Twitter di Cardioinfo

#ACC20/#WCCardio | [2/3] PROVIDE-HF was a prospective study of HFrEF outpatients initiated on sac/val vs controls with recent initiation/change in ACE/ARB dose at PCORnet centers (a national research network).

Ieri dal Twitter di Cardioinfo

#ACC20/#WCCardio | [1/3] 1205-135 - PROVIDE-HF: In a prospective US study of HFrEF, sacubitril/valsartan initiation was associated with early improvements in QOL. Patients were more likely to have a large improvement in KCCQ (>20-pt) than with ACE/ARB. @robmentz

Ieri dal Twitter di Cardioinfo

#ACC20/#WCCardio | [3/3] Kaplan-Meier curves showed higher total bilirubin was associated with higher incidence of all outcomes. After randomization, conventional LFTs were significantly less in sacubitril/valsartan group compared with enalapril.

Ieri dal Twitter di Cardioinfo

#ACC20/#WCCardio | [2/3] 8238 patients were enrolled from the PARADIGM-HF trial. The authors evaluated the impact of LFTs on the incidence of primary endpoint (HF hospitalization and cardiovascular (CV) death) and all-cause death, and the effect of sacubitril/valsartan on LFTs.

Ieri dal Twitter di Cardioinfo